Compare Novo Nordisk A/S (NVO) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Novo Nordisk A/S trades at $45.05 (market cap $198.57B), while Direxion Daily Semiconductor Bear 3X Shares trades at $44.89. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| NVO | SOXS | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $1.29K |
52-Week Low | $35.29 | $32.50 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $44.09, down 4.86% in the past 24 hours amid a bearish technical signal. The stock is approaching key support at $43 after a 1:10 stock split effective July 15, 2026. Recent news highlights its volatility as an inverse ETF benefiting from semiconductor sector weakness, though technical indicators show mixed signals with RSI neutral and ADX suggesting a weakening trend.
The outlook remains highly speculative due to SOXS's leveraged inverse structure, which amplifies losses in rising markets. Risks include persistent AI-driven semiconductor demand and the ETF's decay over time. It is suited only for short-term tactical bearish bets, not long-term investment, with current sentiment cautioning against entry without clear technical breakdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
